Germany's GKV cannabis cut draws DHV backlash over reimbursement

Germany narrows GKV cannabis reimbursement

For readers outside Germany, GKV is the country’s statutory health insurance system, and this vote changes what it will pay for when medical cannabis is prescribed. The DHV says Germany’s Bundestag and Bundesrat have sharply narrowed reimbursement: cannabis flowers lose coverage, and a late tightening excludes compounded medicines from reimbursement in the first six months of treatment.

The DHV’s before-and-after picture is easier to read in table form:

Three numbers show how tightly the field has been reduced:

That is why the association frames the decision as more than a technical change. It is a cut in choice at the exact point where patients and prescribers are deciding how to start treatment.

The committee route behind the final text

DHV says the final text was not just the result of a clean administrative process. According to the association, a CSU initiative drove the tightening and the recommendation was then carried by votes from CDU, CSU and SPD in Germany’s health committee.

The timeline the DHV describes looks like this:

The hearing matters because it showed the direction of travel before the vote. On 22 June 2026, Hecken argued for a six-month period in which compounded medicines would not be reimbursed and explicitly named Exilby, the newly approved product from Munich company Vertanical, as a possible alternative.

DHV also says Vertanical founder and shareholder Clemens Fischer had donated €200,000 to the CSU, €100,000 to the SPD and €90,000 to the CDU before the last federal election.

This is something I have never seen in 24 years as DHV chair.

Georg Wurth

The donations DHV cites are broken down like this:

Taken together, the association’s complaint is that the policy signal and the product signal point in the same direction: away from plant-based reimbursement, and toward a single named finished medicine with an unsettled price.

What insured patients lose at the prescription stage

For insured patients, the practical effect is blunt. DHV says many people who already had reimbursement for cannabis flowers will not find an adequate replacement in the remaining options, and the new setup does not include an inhaled route for pain spikes.

The association’s main patient concerns are:

• Reimbursement for medical cannabis flowers is removed.
• All compounded cannabis medicines are excluded from reimbursement in the first six months of treatment.
• The only THC finished medicines left for therapy start are Sativex and Exilby.
• DHV says neither of those options offers an inhaled route for pain spikes.

At the pharmacy counter, the change will be visible in paperwork and reimbursement decisions rather than headlines:

That is the point DHV keeps returning to: this is a restriction in the day-to-day mechanics of treatment, not just a symbolic vote in Berlin.

Exilby's launch price sits at the centre of the dispute

The pricing debate is why the decision around Exilby matters beyond one product name. As we explained in our earlier explainer on how Germany sets the price of a cannabis finished medicinal product, the opening months of a launch are controlled by the company, not by a negotiated insurer price.

A company-controlled window before insurer talks

DHV says Exilby has no negotiated price with the health insurers yet. For the first six months, Vertanical alone sets the price; only after that does the company negotiate an reimbursement amount with Germany’s GKV-Spitzenverband. That is why the actual cost to statutory insurers is still open.

On the DHV’s reading, that produces three problems:

1. Moving from flowers to finished medicines does not obviously save money.
2. The statutory funds cannot yet see the final reimbursement price for Exilby.
3. A savings-driven rule looks hard to square with recommending a product whose insurer price is still unknown.

The association’s bottom line is simple: a narrower menu for patients, and no clear evidence that Germany’s statutory system will spend less.

The remaining questions for patients and insurers

Readers will likely come back to the same three questions: who can still start treatment, what is covered at the start, and how much this new framework will cost once the price settles.